key: cord-0708127-62x38051
authors: Saeed, Omar; Tatooles, Antone J.; Farooq, Muhammad; Schwartz, Gary; Pham, Duc T.; Mustafa, Asif K.; D’Alessandro, David; Arbol, Sunil; Jorde, Ulrich P.; Gregoric, Igor D.; Radovancevic, Rajko; Lima, Brian; Bryner, Benjamin S.; Ravichandran, Ashwin; Salerno, Christopher T.; Spencer, Philip; Friedmann, Patricia; Silvestry, Scott; Goldstein, Daniel J.
title: Characteristics and Outcomes of Patients with COVID-19 Supported by Extracorporeal Membrane Oxygenation: A Retrospective Multicenter Study
date: 2021-05-18
journal: J Thorac Cardiovasc Surg
DOI: 10.1016/j.jtcvs.2021.04.089
sha: ba0a472eeadce58814053ae52aac365704d0ac36
doc_id: 708127
cord_uid: 62x38051

Objective To determine characteristics, outcomes and clinical factors associated with death in patients with coronavirus disease 2019 (COVID-19) requiring ECMO support. Methods A multicenter, retrospective cohort study was conducted. The cohort consisted of adult patients (≥18 years old) requiring ECMO in the period from March 1, 2020 to September 30, 2020. The primary outcome was in-hospital mortality after ECMO initiation assessed through a time to event analysis at 90 days. Multivariable Cox proportional regression was utilized to determine factors associated with in-hospital mortality. Results Overall, 292 patients from 17 centers comprised the study cohort. Patients were 49 (IQR: 39-57) years old and 81 (28%) were female. At the end of the follow up period, 19 (6%) patients were still on ECMO, 25 (9%) were off ECMO but remained hospitalized, 135 (46%) were discharged or transferred alive and 113 (39%) expired during the hospitalization. The cumulative in-hospital mortality at 90-days was 42% (95% CI: 36-47%). Factors associated with in-hospital mortality were age (aHR: 1.31, 95% CI: 1.06-1.61 per 10 years), renal dysfunction as measured by serum creatinine (aHR: 1.21, 95% CI 1.01-1.45) and cardiopulmonary resuscitation prior to ECMO placement (aHR: 1.87, 95% CI 1.01-3.46). Conclusions In patients with severe COVID-19 necessitating ECMO support, in-hospital mortality occurred in fewer than half of the cases. ECMO may serve as a viable modality for terminally ill patients with refractory COVID-19.

Although ECMO can often lead to normalization of gas exchange and acid-base status and it 137 may provide time for resolution of the pulmonary insult, its use is associated with major 138 complications including bleeding, thrombosis, infection and stroke, which collectively occur in 139 the majority of cases. 5 Moreover, ECMO is highly resource intensive and most implanting 140 centers can only offer such mechanical support to a limited number of patients. 141 In the early COVID 19 experience in 2020, scant reports and single center series of outcomes 142 with ECMO showed variability in mortality ranging from 25-90%. [6] [7] [8] [9] [10] [11] Despite the absence of 143 rigorous and adjusted outcomes data, ECMO was suggested for appropriate patients with 144 COVID-19 and was commonly utilized by experienced centers in the United States (US). 12 A data capture tool was created using REDCap for record entry by the participating centers.

Data fields included demographics, laboratory parameters, ECMO characteristics and patient 164 outcomes. All data were anonymised. Prior to data entry, sites were individually familiarized 165 with the data capture tool and consistency was ensured by continuous technical support provided 166 by the corresponding author at the data coordination center throughout the data collection period.

To maintain accuracy, the data capture fields contained checks for validity such as input masks 168 and range rules for date fields and branching logic. Data consistency was maintained through Table S1 . Since LDH was missing in >10% of the patients, we created a categorical variable Figure S1 ).

Outcomes 253

The cumulative incidence of in-hospital mortality at 90 days after ECMO initiation was 42% 254 (95% CI: 36-47%, Figure 5 ). This incidence of in-hospital death remained similar at 42% (95% The principal findings of this largest to date US experience with ECMO use during COVID-19 280 are as follows: 1) death during hospitalization occurred in less than half of the patients; 2) 281 patients discharged or transferred alive were placed on ECMO sooner after admission than those 282 that expired; 3) advancing age, renal injury and cardiopulmonary arrest requiring CPR during 283 admission previous to ECMO placement forecasted reduced survival; 4) secondary infections 284 occurred in majority of the patients; and 5) over 80% of the patients discharged or transferred 285 alive were either sent home or to a rehabilitation facility. Regional variation in hospital 286 mortality is likely multifactorial and may be related to the initial burden of the pandemic in the 287 J o u r n a l P r e -p r o o f US, which was greatest in the Northeast. The lack of association between potential COVID-19 288 therapeutics and survival, in particular steroids, which have been shown to reduce mortality in 289 hospitalized patients 17 could be related to the extreme severity of illness in patients undergoing 290 ECMO support; however, the efficacy of such regimens cannot be determined by our registry-291 based study design and with concurrent administration of multiple therapies.

Our findings showed a similar cumulative incidence of in-hospital mortality at 90 days for 293 patients with COVID-19 requiring ECMO in comparison to the worldwide experience in the 294 ELSO registry, reported as 37% 16 , which persisted after exclusion of overlapping centers.

Although both studies contain patients with a similar age distribution, burden of co-morbidities 296 and levels of disease severity as evidenced by comparable PaO 2 /FiO 2 ratios, small differences in 297 outcome may be related to local unmeasured variations in patient selection and practices.

Similar to the worldwide ELSO experience, we also noted that stroke occurred in 7% of the 299 cases, with the bleeding subtype as most common, as is also apparent in non-COVID-19 300 patients. 5,18 As an external validation for the international ELSO study, this US-based 301 experience provides corroborative evidence that ECMO support may lead to the survival for 302 majority of the patients afflicted by COVID-related ARDS. Survivors received ECMO sooner during admission than patients that expired. We speculate that 330 this finding may relate to relatively more rapid restoration of oxygenation and limitation of 331 irreversible end organ damage earlier during illness by ECMO placement. Thus, in appropriate 332 candidates with refractory respiratory failure from COVID-19, early ECMO may potentially improve outcomes. Beyond survival, and in light of the elevated burden of adverse events 334 including infection and renal replacement therapy during ECMO support, it remains essential to 335 determine the long-term functional and readmission outcomes of patients that were discharged or 336 transferred alive. In our study, 54 (40%) and 20 (15%) of the patients that were discharged or 337 transferred alive, were sent to a rehabilitation facility or another health care facility, respectively.

Further follow-up of these patients is warranted and will inform if ECMO is indeed an effective 339 mode of therapy to reach meaningful recovery and quality of life. Table 3 to pave the path towards improving outcomes.

In summary, our findings indicate that ECMO may serve as a useful method of advanced 357 pulmonary support in patients with refractory respiratory failure from COVID-19. These data 358 provide further credence for usage of ECMO in appropriate patients with severe COVID-19 and 359 reinforce resource allocation towards this beneficial modality. 

-Risk score models to stratify prognosis at cannulation and during ECMO support. Advanced age, renal injury and prior cardiopulmonary resuscitation would be considered in these models.

-Goals of care assessment -Standardization of cannulation criteria

-Development and assessment of clinical pathways to closely monitor tenuous ventilated patients such as those with a PaO2/FiO2 ratio ≤100 for early ECMO within 48-72 hours of presentation -Determination of optimal anatomical cannulation sites -Assessment of outcomes with cannulation through a RVAD-ECMO vs. conventional ECMO configuration -Comparison of differing hospital areas for ECMO cannulation

-Optimal anticoagulation methods with comparison of differing pharmacotherapies -Transfusion goals -Impact of renal replacement therapy on outcomes -Assessing benefit of attempting early extubation -Appropriateness and timing of tracheostomy and comparison of percutaneous vs. open technique -Timing and thresholds of ECMO weaning for recovery or futility -Evaluation of multidisciplinary teams for improving outcomes

-Assessment of long-term functional outcomes

Covid-19 in Critically Ill Patients in the

Seattle Region-Case Series

Presenting characteristics, comorbidities, 430 and outcomes among 5700 patients hospitalized with COVID-19 in the New York City 431 area

Acute complications and mortality in 433 hospitalized patients with coronavirus disease 2019: a systematic review and meta-434 analysis

Extracorporeal membrane oxygenation for adult respiratory failure: 436 2017 update

Systematic review and meta-438 analysis of complications and mortality of veno-venous extracorporeal membrane 439 oxygenation for refractory acute respiratory distress syndrome

Extracorporeal Membrane Oxygenation in the 442 Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience 443 with 32 patients

Ñamendys-Silva SA. ECMO for ARDS due to COVID-19. Heart & Lung: The Journal 462 of Cardiopulmonary and Acute Care

A note on 464 competing risks in survival data analysis

A class of K-sample tests for comparing the cumulative incidence of a 467 competing risk. The Annals of statistics

Extracorporeal membrane oxygenation 469 support in COVID-19: an international cohort study of the Extracorporeal Life Support 470 Organization registry

Dexamethasone in hospitalized patients with Covid-19

A meta-analysis of complications and 474 mortality of extracorporeal membrane oxygenation

Extracorporeal life support for adults with respiratory 477 failure and related indications: a review

Predicting survival after extracorporeal 479 membrane oxygenation for severe acute respiratory failure

Efficacy and economic assessment of 483 conventional ventilatory support versus extracorporeal membrane oxygenation for severe 484 adult respiratory failure (CESAR): a multicentre randomised controlled trial. The Lancet

Extracorporeal membrane oxygenation for 487 severe acute respiratory distress syndrome

Venovenous 490 extracorporeal membrane oxygenation for acute respiratory distress syndrome: a

Protein (mg/dl)

Number observations for each variable are listed in supplemental table 1. Percentages represent the proportion of reported observations. Continuous variables are displayed as median (Q1-Q3), *p<0.05. Blood gas parameters were measured prior to ECMO placement

6 (4-8) 7 (6-10) 6 (4-7) 6 (4-8) 6 (3-8)

2 (1-7) 6 (0-10) 3 (0-9) 1 (1-5) 4 (1-10)*

3